

A Study of Hematological Profile in Patients of Chronic Renal Failure Undergoing Hemodialysis at a Tertiary Health Care Institute

Arjun Chakravarti¹, Archana Ukey^{2*}, Preeti Bajaj³ and Pradnya Saragade¹

¹PG resident, Department of Pathology, Dr.Vasantrao Pawar Medical College Hospital & Research Centre, Nashik -422003, Maharashtra, India ; achakravarti2100@gmail.com

²Associate Professor, Department of Pathology, Dr.Vasantrao Pawar Medical College Hospital and Research Centre, Nashik -422003, Maharashtra, India ; archu12241@gmail.com

³Professor and Head, Department of Pathology, Dr.Vasantrao Pawar Medical College Hospital & Research Centre, Nashik -422003, Maharashtra, India ; dr.prbajaj@gmail.com

Abstract

The complete blood count, peripheral blood smear, bleeding time, clotting time and renal function tests of 114 patients of chronic renal failure who had required hemodialysis for a period of at least 3 months prior to the commencement of this study were studied. The purpose of this study was to investigate the derangements in the haematological profile of chronic renal patients undergoing hemodialysis and to correlate the same with the duration and severity of the renal failure. The principal finding in the study was a 100% prevalence of anemia among chronic renal failure patients, which was predominantly of the normocytic normochromic type. Red blood cell count was reduced in nearly all (93%) of study patients. There was also a strong negative correlation ($r = -0.74$) between haemoglobin and duration of hemodialysis. However, a significant proportion of cases showed abnormal cells in the peripheral blood cells such as burr cells, schistocytes and pencil cells, suggesting other contributing factors to the anemia. Female patients also showed a significantly greater prevalence of increased red cell distribution width ($>15\%$) as compared to males ($p = 0.001$) and a lower prevalence of normocytic normochromic anemia as compared to males ($p = 0.009$). White blood cell counts, platelet counts, and bleeding and clotting times were largely within normal limits, and none of these variables showed a statistically significant association with the duration of hemodialysis, or serum creatinine, or serum blood urea nitrogen. The inference from the study is that anemia is a major comorbidity in end-stage renal failure patients, with many factors contributing to it, and detailed workup and effective treatment of anemia is necessary in this group of patients.

Keywords: Anemia, Bleeding Time, Clotting Time, Complete Blood Count, Hemodialysis, Normocytic Normochromic

1. Introduction

The prevalence of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) is rising rapidly throughout the world, including India. It is estimated that as of 2015, 55,000 Indians are on hemodialysis, with the number rising by 10-20% each year¹.

The US National Kidney Foundation's Kidney Dialysis Outcomes Quality Initiative (K/DOQI) guideline defines CKD as kidney damage or estimated glomerular filtration rate (eGFR) of < 60 ml/min/1.73 m² for > 3 months. Kidney damage is defined as pathological abnormalities or markers of damage including blood, urine or imaging tests².

Rajapurkar MM, et al³ found diabetic nephropathy to be the predominant (31% of cases) cause of CKD in patients from all over India.

NKF/KDOQI guideline (2002) defines anemia in Chronic Kidney Disease when the hemoglobin level is < 13.0 g/dl in adult males and 12.0g/dl in adult females².

The major cause of anemia in CKD is lack of erythropoietin (EPO) synthesis in the diseased kidneys. As renal disease progresses, specialized peritubular cells that produce EPO are depleted or injured, resulting in inappropriately low EPO comparative to the degree of anemia, which is usually of the normocytic normochromic type⁴.

The coagulation profile of CKD patients may also be

affected as CKD advances. In a study by Subhan-ud-din and Shahida A.R. Shah⁵, bleeding time (BT), prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count and D-dimer levels were evaluated in 100 CKD patients. 93% of the patients had elevated D-Dimer levels, and platelet count was reduced compared to controls, however, BT, PT and aPTT time were not significantly different from controls.

2. Materials and Methods

A total of 114 cases were studied. All of the patients had been undergoing hemodialysis for ESRD for at least 3 months prior to the commencement of the study and were in the age range of 18-75 years. None of the patients had any known acute illness or chronic haematological disorder.

The CBC of each patient was done on a 5-part Beckman Coulter automated hematology analyzer. Peripheral blood smears were made and stained with Field's and Leishman stain, and examined for RBC, WBC and platelet morphology.

Predialysis serum creatinine (sr. creat) and serum blood urea level (sr. BUL) were also obtained for each patient.

The bleeding time of each patient was recorded by giving a 5mm deep puncture on the fingertip followed by pressure on a blotting paper at 30 second intervals. The time taken for bleeding to stop was noted.

The clotting time was recorded by aspirating blood (from the 5mm puncture given for the bleeding time) into a thin capillary tube. The tube was intermittently tilted below the horizontal, and the time taken for the blood to stop flowing was noted.

3. Results

3.1 Age, Sex, History, Duration of Dialysis and RFTs

The total number of cases in the study was 114. The mean age of the subjects was 43.36+/- 11.24 years, with a range of 18-75 years. 65.79% of the study subjects were male.

95.61% of the study subjects had hypertension, and 60.53% had diabetes mellitus. Only 16.67% had comorbidities likely to contribute to CKD, such as chronic glomerulonephritis, renovascular disease, obstructive uropathy etc.

The mean duration of hemodialysis was 1.78+/-0.81 years, with a range of 0.5-4 years.

The mean predialysis serum creatinine value was 7.87+/-2.25 mg/dl, with a range of 3.1 – 20mg/dl.

The mean serum BUL was 130.33+/-34.83 mg/dl, with a range of 78-252 mg/dl.

3.2 Anemia

Anemia as defined by WHO criteria⁶ was present in 100% of the subjects. The mean Hb level was 7.39+/- 1.7mg/dl. 5.26% of the patients had mild anemia, 55.26% had moderate anemia and 39.47% had severe anemia according to WHO criteria⁶.

As seen, 77.19% of the study subjects had normocytic normochromic anemia, and males had a greater prevalence of normocytic normochromic anemia than females, which was statistically significant (p = 0.009).

Females had a greater prevalence of abnormal RBCs on peripheral smears than males, especially of pencil cells.

The mean RBC count was 2.78+/-0.74 millions/cmm.

Table 1. Prevalence of various types of anemia

Anemia based on Morphology	Females (39)		Males (75)		Total (114)	
	No.	%	No.	%	No.	%
Dimorphic Anemia	11	28.21	6	8.00	17	14.91
Microcytic Hypochromic	4	10.26	3	4.00	7	6.14
Macrocytic Anemia	0	0.00	2	2.67	2	1.75
Normocytic Normochromic Anemia	24	61.54	64	85.33	88	77.19
Total	39	100.00	75	100.00	114	100.00

Chi sq. = 11.58, p value = 0.009*

Table 2. Prevalence of various type of abnormal red blood Cells

Abnormal RBCs	Females (39)		Males (75)		Total (114)	
	No.	%	No.	%	No.	%
Pencil Cells	10	25.64	2	2.67	12	10.53
Fragmented RBCs	5	12.82	4	5.33	9	7.89
Burr Cells	14	35.90	23	30.67	37	32.46
Macro-Ovalocytes with Hypersegmented Neutrophils	4	10.26	4	5.33	8	7.02
Normocytic Normochromic RBCs	24	61.54	64	85.33	88	77.19

Table 3. Prevalence of normal and increased RDW

Red Cell Distribution Width (RDW)	Females (39)		Males (75)		Total (114)	
	No.	%	No.	%	No.	%
>15% (Anisocytosis)	26	66.67	26	34.67	52	45.61
Normal (10-15%)	13	33.33	49	65.33	62	54.39
Total	39	100.00	75	100.00	114	100.00

Chi sq. = 10.59, p value = 0.001*

Table 4. Pearson correlation between severity of anemia and duration of dialysis, serum creatinine & serum BUL among study patients

		Duration of Dialysis	Creatinine	BUL	Haemoglobin
Duration of Dialysis	Pearson Correlation	1	.379**	.489**	-.743**
	Sig. (2-tailed)		.000	.000	.000
	N	114	114	114	114
Creatinine	Pearson Correlation	.379**	1	.665**	-.383**
	Sig. (2-tailed)	.000		.000	.000
	N	114	114	114	114
BUL	Pearson Correlation	.489**	.665**	1	-.518**
	Sig. (2-tailed)	.000	.000		.000
	N	114	114	114	114
Haemoglobin	Pearson Correlation	-.743**	-.383**	-.518**	1
	Sig. (2-tailed)	.000	.000	.000	
	N	114	114	114	114

** . Correlation is significant at the 0.01 level (2-tailed).

93% of the study patients had a low RBC count (below 4 millions/cmm).

The mean red cell distribution width was 15.08+/- 2.39%. Females had a greater prevalence of increased RDW (>15%) compared to males, and this difference was statistically significant (p = 0.001).

The above table shows strong negative correlation between haemoglobin and duration of dialysis (r = -0.74, p = 0.00), weak negative correlation between haemoglobin and creatinine (r = -0.38, p = 0.00) and moderate negative correlation between haemoglobin and BUL (r = -0.52, p = 0.00).

Pearson correlation test also showed moderate negative between RBC count and duration of dialysis (r = -0.59, p = 0.00) and serum BUL, (r = -0.48, p = 0.00) & weak negative correlation between RBC count and serum Creatinine (r = -0.37, p = 0.00).

An ANOVA test showed that mean duration of dialysis, serum creatine and serum BUL were all significantly higher (p < 0.05) in patients having fragmented RBCs and burr cells in their peripheral smears as compared to patients without these cells.

3.3 WBCS

The mean WBC count was 7968+/-4843/cmm. 15.79% of the patients had leukocytosis (total WBC count > 11000/cmm) (which was neutrophilic leukocytosis in all cases)

and 16.67% of the patients had leukopenia (total WBC count < 4000/cmm). Also, 6.14% of patients showed eosinophilia (defined as absolute eosinophil count > 500/cmm), 3.51% had relative lymphocytosis (greater percentage of lymphocytes than neutrophils), and 4.39% had hyper segmented neutrophils (defined⁷ as more than 3% of neutrophils with five lobes, and/or at least one neutrophil with 6 or more lobes)

On Pearson correlation, no correlation was found between WBC count and duration of dialysis (r = 0.16, p = 0.08), serum creatinine (r = 0.11, p = 0.24) or serum BUL (r = 0.14, p = 0.15). Also, on ANOVA, duration of dialysis (p = 0.83), serum creatinine (p = 0.93) and serum BUL (p = 0.69) did not differ significantly between patients having various types of WBC morphology.

3.4 Platelets

The mean platelet count was 2.26+/- 1 lakh/cmm. Thrombocytopenia (platelet count < 1.50 lakhs/cmm) was present in 13.16% of patients, while thrombocytosis (platelet count > 4.50 lakhs/cmm) was present in 1.75% of patients. 9.65% of patients showed macroplatelets on peripheral smears.

On Pearson correlation, there was no correlation between platelet counts and duration of dialysis (r = 0.022, p = 0.82), serum creatinine (r = 0.024, p = 0.79) and serum BUL (r = -0.052, p = 0.58). Unpaired t-test also

showed no association between presence or absence of giant platelets and duration of dialysis ($p = 0.54$), serum creatinine ($p = 0.96$) and serum BUL ($p = 0.39$).

3.5 Bleeding and Clotting Times

The mean bleeding time was 6.75 ± 1.79 minutes. 10.53% of the patients had an abnormal bleeding time (> 9 mins). There was no significant difference between patients with normal and abnormal bleeding times with respect to duration of dialysis ($p = 0.96$), serum creatinine ($p = 0.96$) and serum BUL ($p = 0.69$).

The mean clotting time was 4.95 ± 0.99 minutes. 13.16% of patients had an abnormal clotting time (> 6 mins). There was no significant difference between patients with normal and abnormal clotting times with respect to duration of dialysis ($p = 0.06$), serum creatinine ($p = 0.57$) or serum BUL ($p = 0.66$).

4. Discussion

The majority of study subjects were males (65.79%), similar to studies by Arun S et al⁸, Chinwuba et al⁹, MN Islam et al¹⁰, and Bhattacharjee K et al¹¹.

The mean age in this study was 43.36 ± 11.24 years, similar to Chinwuba et al⁹ and MN Islam et al¹⁰ respectively.

4.1 Etiology of CKD

Hypertension and diabetes mellitus were identified as the main causes for CKD in this study; 109 (95.6%) of the patients had hypertension and 69 (60.5%) had diabetes mellitus. This was similar to studies by Bhatta S et al¹², and George SV et al¹³. However, Chinwuba et al⁹ found the prevalence of hypertension (22.5%) and diabetes mellitus (15.1%) to be lower than that of chronic glomerulonephritis (37%) among CKD patients in that study.

4.2 Anemia

In this study, all the patients were anemic. The mean haemoglobin level was 7.39 ± 1.7 g/dl. This finding was in concordance with the studies by Bhatta S et al¹², Barde R et al¹⁴, Hakim et al¹⁵ and Bhattacharjee K et al¹¹.

The prevalence of mild, moderate and severe anemia by WHO criteria⁶ was 5.26%, 55.26% and 39.48% respectively.

In this study, 77.19% of all the patients had normocytic normochromic anemia, similar to the studies by Arun S et al⁸, Mudiyanmanavara NR, et al¹⁶, George SV et al¹³, Bhattacharjee K et al¹¹ and Reza A et al¹⁷, but contrasting

with studies such as Tennankore KK et al¹⁸, which found a prevalence of MCV > 97 fl of 61%, and MCV > 102 fl of 30%, and Talwar et al¹⁹ which found a 60% prevalence of microcytic hypochromic anemia among CKD patients.

Duration of dialysis, serum creatinine and serum BUL were significantly higher in patients with fragmented RBCs ($p < 0.05$) and burr cells ($p < 0.05$). Burr cells are known to increase in proportion to the severity of uremia²⁰ while fragmented RBCs suggest a hemolytic component, which could be due to reasons like decreased adenosine triphosphatase activity in the RBC membrane²¹, decreased red cell survival in uremia²², or even toxins in the dialysate itself such as copper, nitrates and formaldehyde²³.

4.3 WBCs

The mean WBC count in this study was within the normal range. 15.79% of the patients had neutrophilic leukocytosis. Other studies such as George SV et al¹³ and Rathod SG²⁴ also show a considerable number of ESRD patients showing neutrophilic leukocytosis. This may be due to the high incidence of latent or secondary infection in these patients.

4.4 Platelets

The mean platelet count in this study was within the reference range. 13.16% of the patients had thrombocytopenia while 1.75% had thrombocytosis.

Gafer U et al²⁵ found the mean platelet count among ESRD patients to be significantly reduced (1.75 ± 0.065 lakhs/cmm) compared to controls.

Another study by Dorgalaleh et al²⁶ found the mean platelet count in CKD patients to be 1.72 ± 0.9 lakhs/cmm and reduced compared to controls. Other studies show platelet dysfunction in many cases of ESRD which predisposes the patients to bleeding^{27,28}.

4.5 Bleeding and Clotting Times

The mean bleeding and clotting times in this study were within the reference ranges. 10.53% of the patients had an increased bleeding time (> 9 mins) while 13.16% of the patients had an increased clotting time (> 6 mins).

A study by Butt M et al²⁹ found increased bleeding time in 33% of patients on hemodialysis, which is higher than in this study, although hemodialysis improved the bleeding time in many patients. Subhan-ud-din and Shahida A.R. Shah⁵ found that, no stage III CKD patients and only 10% of stage IV CKD patients had an abnormal bleeding time. Also the PT and aPTT were normal in all the patients in that study. By contrast, Ramaprabha P et al³⁰ found a significant elevation of PT, aPTT and plasma fibrinogen

levels in ESRD patients as compared to controls, as well as a decrease in platelet count.

One study³¹ showed improvement of the bleeding time consequent to correction of anemia with ESAs (Erythropoietin Stimulating Agents). So the overall inference is that there is a bleeding tendency in ESRD, despite normal platelet count.

5. Conclusion

This study showed a 100% prevalence of anemia in patients on hemodialysis. It was predominantly of the normocytic normochromic type, suggesting EPO deficiency as the primary cause. However, in some cases, the presence of abnormal cells such as fragmented RBCs, pencil cells and macro-ovalocytes suggest other contributory factors, such as hemolysis, iron deficiency or folate/vitamin B12 deficiency. Neutrophilic leukocytosis in some patients may be explained by the tendency towards latent or secondary infections. Although the platelet counts, bleeding and clotting times were largely normal in this study, some studies suggest otherwise. In the light of this study, there is a need for nephrologists to monitor the haematological profile of CKD patients on dialysis, and treat any derangements in the same, so as to improve outcome for these patients.

6. References

- Jha V, et al. Current status of end stage renal disease core in India. *Kidney International Supplements*. 2013; 3:157–60. <https://doi.org/10.1038/kisup.2013.3>
- National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*, 2002; 39:1–266. PMID:11774095
- Rajapurkar, et al. What do we know about chronic kidney disease in India: First report of the Indian CKD registry. *BMC Nephrology*. 2012; 13:10. <https://doi.org/10.1186/1471-2369-13-10> PMID:22390203 PMCid:PMC3350459
- McGonigle RJ, Shaddock RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. *Kidney Int*. 1984; 25:437–44. <https://doi.org/10.1038/ki.1984.36> PMID:6727139
- Subhan-ud-din, Shah SAR. Haemostatic defects in chronic kidney disease. *J Med Sci*. 2013 Jul; 21(3):149–52.
- World Health Organization. Iron deficiency anemia: Assessment, prevention and control. A guide for programmer manager; Geneva: WHO 2001. Available from: http://apps.who.int/iris/bitstream/10665/66914/1/WHO_NHD_01.3.pdf?ua=1
- Palmer L, et al. ICSH recommendations for the standardization of nomenclature and grading of peripheral blood cell morphological features. *Int Jnl Lab Hem*. 2015; 37:287–303. <https://doi.org/10.1111/ijlh.12327> PMID:25728865
- Arun S, Prabhu MV, Chowta KN, Bengre ML. The hematological pattern of the patients with chronic kidney disease in a tertiary care setup in South India. *Journal of Clinical and Diagnostic Research*. 2012 Aug; 6(6):1003–6.
- Chinwuba I, Uchenna I, Ngozi I. High prevalence of anemia in predialysis patients in Enugu, Nigeria. *Nephrology Reviews*. 2010; 2:14.
- Islam MN, FerdousA, Zahid AZ, Alam M, Islam MN. Haematological profile of patients with chronic kidney disease in Northern Bangladesh. *Dinajpur Med Col J*. 2015 Jan; 8(1):21–7.
- Bhattacharjee K, Das D, Rabha P, Kalwar AK, Kar G, Bhattacharjee P. A study on hematological profile in patients of chronic renal failure with special reference to serum iron profile. *Journal of Evidence based Medicine and Healthcare*. 2015; 2(46):8212–9. <https://doi.org/10.18410/jebmh/2015/1107>
- George SV, Pullockara JK, Sailesh KS, Mukkadan JK. A study to assess changes in the hematological profile in chronic kidney disease. *The Pharma Innovation Journal*. 2015; 4(6):1–3.
- Bhatta S, Aryal G, Kafle RK. Anemia in chronic kidney disease patients in predialysis and postdialysis stages. *Journal of Pathology of Nepal*. 2011; 1:26–9. <https://doi.org/10.3126/jpn.v1i1.4446>
- Barde R, Patel HV, Shah PR. A study of anemia prevalence in CKD patients on maintenance hemodialysis: A single centre study. *Journal of Evidence Based Medicine and Healthcare*. 2015; 2(39):6344–48. <https://doi.org/10.18410/jebmh/2015/871>
- Hakim YAH, et al. The effect of hemodialysis on hemoglobin concentration Platelet count and white blood cell count in end-stage renal failure. *Int Journal of Medical Research and Health Sciences*. 2016; 5(5):22–35.
- Mudiyammanavara NR, Dhananjaya PE, Agarwal R. Cross sectional study of anaemia in chronic kidney disease. *Indian Journal of Basic and Applied Medical Research*. 2015 Mar; 4(2):414–9.
- Reza A, Suzan S, Javad S, Mahnaz A. Hematological profile of Chronic Kidney Disease (CKD) patients in Iran, in pre-dialysis Stages and after Initiation of Hemodialysis. *Saudi J Kidney Dis Transpl*. 2009; 20(1):368–71.
- Tennankore KK, Soroka SD, West KA, Kiberd BA. Macrocytosis may be associated with mortality in chronic hemodialysis patients: A prospective study. *BMC Nephrology*. 2011; 12:19. <https://doi.org/10.1186/1471-2369-12-19> PMID:21569355 PMCid:PMC3114714
- Talwar VK, Gupta HL, Shashinarayan. Clinico-haematological profile in chronic renal failure. *The Journal of Association of Physicians of India*. 2002; 50:228–33. PMID:12038654
- Chandra M. Pathogenesis of the anemia of chronic renal failure: The role of erythropoietin. *Nefrologia*. 1990; 10.
- Cole CH. Decreased ouabain-sensitive adenine triphosphatase activity in the erythrocyte membrane of patients with chronic renal disease. *Clin Sci*. 1973; 45:775. <https://doi.org/10.1042/cs0450775>

22. Vos FE, et al. Red blood cell survival in long-term dialysis patients. *Am J Kidney Dis.* 2011; 58(4):591–8. <https://doi.org/10.1053/j.ajkd.2011.03.031> PMID:21715072
23. Orringer EP, Mattern WDL. Formaldehyde-induced hemolysis in chronic hemodialysis. *N Engl J Med.* 1976; 294:416. <https://doi.org/10.1056/NEJM197606242942602> PMID:178999
24. Rathod SG, Ade AK, Shekokar PP. A study of haematological changes in chronic renal failure. *Sch J App Med Sci.* 2014; 2(4A):1232–4.
25. Gafer U, Bessler H, Malachi T, Zevin D, Djaldetti M, Levi J. Platelet count and thrombopoietic activity in patients with chronic renal failure. *Nephron.* 1987; 45(3):207–10. <https://doi.org/10.1159/000184118> PMID:3574570
26. Dorgalaleh A, et al. Anemia and thrombocytopenia in acute and chronic renal failure. *Int J Hematol Oncol Stem Cell Res.* 2013; 7(4):34–9. PMID:24505541 PMCid:PMC3915422
27. Kaw D, Malhotra D. Hematology: Issues in the dialysis patient: Platelet dysfunction and end-stage renal disease. *Seminars in Dialysis.* 2006; 19:317–22. <https://doi.org/10.1111/j.1525-139X.2006.00179.x> PMID:16893410
28. Van Bladel ER, et al. Platelets of patients with chronic kidney disease demonstrate deficient platelet reactivity in vitro. *BMC Nephrology.* 2012; 13:127. <https://doi.org/10.1186/1471-2369-13-127> PMID:23020133 PMCid:PMC3473261
29. Butt M, Shafi T, Farooq IK. Effects of dialysis on bleeding time in chronic renal failure. *J Pak Med ASS.* 1998; 48:242–4.
30. Ramaprabha P, Bhuvanawari T, Kumar RA. Coagulation profiles an indicator of vascular haemostatic function in chronic renal failure patients who are on renal dialysis. *Sch J App Med Sci.* 2014; 2(2B):592–5.
31. Eberst E, Berkowitz LR. Hemostasis in renal disease: Pathophysiology and management. *Am J Med.* 1994; 96:168–79. [https://doi.org/10.1016/0002-9343\(94\)90138-4](https://doi.org/10.1016/0002-9343(94)90138-4)